These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 10179343)

  • 21. Medical device reporting: the US final rule.
    Donawa ME
    Med Device Technol; 1996 Mar; 7(2):14-6, 18, 20-1. PubMed ID: 10159867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human cells, tissues, and cellular and tissue-based products; donor screening and testing, and related labeling. Interim final rule; opportunity for public comment.
    Food and Drug Administration, HHS
    Fed Regist; 2005 May; 70(100):29949-52. PubMed ID: 15915582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical devices; reports of corrections and removals; companion to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Aug; 63(152):42300-4. PubMed ID: 10181727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amendment to the current good manufacturing practice regulations for finished pharmaceuticals. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Dec; 72(232):68064-70. PubMed ID: 18064770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Requirements for testing human blood donors for evidence of infection due to communicable disease agents. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Jun; 66(112):31146-65. PubMed ID: 11725786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigational new drug applications; clinical holds; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Dec; 63(239):68710-2. PubMed ID: 10187560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medical devices; reconditioners, rebuilders of medical devices; revocation of compliance policy guide; request for comments--FDA. Notice.
    Fed Regist; 1998 Dec; 63(233):67076-8. PubMed ID: 10338883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Administrative practices and procedures; internal agency review of decisions; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Jun; 63(115):32772-4. PubMed ID: 10180279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Skin protectant drug products for over-the-counter human use; astringent drug products; final monograph; direct final rule. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(114):35290-3. PubMed ID: 12807133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Status of certain additional over-the-counter drug category II and III active ingredients. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 May; 67(90):31123-5. PubMed ID: 12001971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human tissue intended for transplantation--FDA. Interim rule; opportunity for public comment.
    Fed Regist; 1993 Dec; 58(238):65514-21. PubMed ID: 10131341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness--FDA. Proposed rule.
    Fed Regist; 1998 Oct; 63(195):54082-9. PubMed ID: 10185826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Revisions to the general safety test requirements for biological products--FDA. Direct final rule: confirmation in part and withdrawal in part.
    Fed Regist; 1998 Aug; 63(150):41718. PubMed ID: 10181723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical devices; reports of corrections and removals--FDA. Direct final rule.
    Fed Regist; 1998 Aug; 63(152):42229-33. PubMed ID: 10181725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Child-resistant packaging for certain over-the-counter drug products. Final rule.
    Consumer Product Safety Commission
    Fed Regist; 2001 Aug; 66(149):40111-6. PubMed ID: 11732555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Shiley saga leads to improved communication.
    Farley D
    FDA Consum; 1994; 28(1):12-7. PubMed ID: 10131486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medical devices; preemption of state product liability claims--FDA. Correction.
    Fed Regist; 1997 Dec; 62(242):66179. PubMed ID: 10179302
    [No Abstract]   [Full Text] [Related]  

  • 39. Beverages: bottled water. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 May; 74(102):25651-65. PubMed ID: 19507330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human); companion document to direct final rule. Food and Drug Administration, HHS. Proposed rule.
    Fed Regist; 1999 May; 64(93):26344-8. PubMed ID: 10558531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.